ANEB OTC
Anebulo Pharmaceuticals, Inc.
1W: -1.5%
1M: +6.7%
3M: -13.0%
YTD: -71.7%
1Y: -86.7%
3Y: -90.2%
5Y: -95.4%
$0.32
+0.00 (+0.00%)
Weekly Expected Move ±12.6%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$13.1M
52W Range0.001-2.85
Volume100
Avg Volume2,069
Beta-1.83
Dividend—
Analyst Ratings
Company Info
CEORichard Anthony Cunningham
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2021-05-07
Websiteanebulo.com
1017 Ranch Road 620 South
Lakeway, TX 78734
US
Lakeway, TX 78734
US
512 598 0931
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The companyâs lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Latest News
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 3.5% – Here’s What Happened
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next?
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lawler Joseph F. | A-Award | 25,000 | $1.02 | 2025-04-04 |
| Lawler Joseph F. | A-Award | 13,236 | $1.02 | 2025-04-04 |
| SHAH BIMAL R. | A-Award | 25,000 | $1.02 | 2025-04-04 |
| SHAH BIMAL R. | A-Award | 6,618 | $1.02 | 2025-04-04 |
| Cundy Kenneth C | A-Award | 115,037 | $1.02 | 2025-04-04 |